Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
One review of GLP-1 mechanisms showed reduced inflammatory markers and improved adipose tissue signaling in metabolic conditions, as seen in a recent research review
Research indicates that a meaningful percentage of weight lost on GLP-1 receptor agonists can come from lean tissue rather than adipose tissue, particularly without resistance guidance, adequate protein intake, or physician-directed dose titration
The key molecule class segments in the obesity GLP-1 market are semaglutide, tirzepatide, and other GLP-1 receptor agonists
Physician-Backed Solutions Meet the Founder "As a physician specializing in metabolic health and obesity medicine, I've created these products to address the root causes of metabolic dysfunction
The studies investigated a range of GLP-1 receptor agonists as shown in Table 3: Liraglutide: Used in 3 studies, making it the most frequently tested GLP-1 for GDM
To date, these GLP-1 drugs have been approved to treat three adult populations: individuals with type 2 diabetes, individuals with a body mass index (BMI) of 30 or greater (obesity), and individuals with a BMI between 27 and 30 (overweight) with at least one weight-related health condition, such as cardiovascular disease, high blood pressure, high cholesterol, prior stroke, prior heart attack, and chest pain (angina)
